Latest Earnings Results: Q2 '26
Estimated EPS
-$0.12
Reported EPS
-$0.06
Surprise
+50%
Estimated Rev
$26.21M
Reported Rev
$27.18M
Surprise
+3.71%
Vaxart reported total revenue of $27.2 million for the quarter ended June 30, 2026, and a net loss of $13.5 million, with cash, cash equivalents, and short-term investments of $64.0 million.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.17 | -- | -- | N/A |
Q2 '26 | -$0.12 | -$0.06 | 50.00% | BEAT |
Q1 '26 | $0.02 | $0.02 | -- | EXPECTED |
Q4 '25 | -$0.05 | -$0.11 | -120.00% | MISSED |
Q3 '25 | -$0.07 | -$0.04 | 42.86% | BEAT |